Ideas For Now-

<<<< :cool:6 PACK+1 DRINK UP!:cool: >>>>


LAZR-- THOUGHT: Maybe we go for it?

VLDR-- Kind of yesterday's trade. But they have earnings of some sort.

UTZ-- You know it's going to be boring and take up space.

DTEA-- Probably missed this one

GDDY-- I think this is going to $100.

SPRO-- I'm kind of interested. Urinary tract infections happen and to be treated at home would be huge! It keeps people out of hospitals and this is a theme we can work...and it's potentially a $1b product my experience in biotech is that's a good word. Sometimes I'm risking so much and my end market is $30 mln....

AQUA-- Again this company interests. They have some ways of being a play on reopening....
 
Wow I think we struck gold with SPRO. What I didn't get and I now understand is outside of a normally huge patient population there are all these folks who are already on an antibiotic and need something new (2 mil) // They appear to have $127 mil in cash little Debt 7.9% shares short of a tight share count 19 mil float 3/4 tied up. Low Volume. Pill that is like an IV is a good marketing theme. CEO seems very bright. Timing -- 2H of 2021 looks like.... This is a perfect stock for the Ideas For Now Portfolio....
 
Chart is interesting as well.... A huge volume day would get everyone's attention. This stock has gone relatively unnoticed.

Check this old Analyst comment from Nov-- $33 PT! / Stk is about to hit $18 in the pre market<--))))))))

Spero Therapeutics price target raised to $33 from $28 at H.C. Wainwright 11/23 SPRO H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Spero Therapeutics to $33 from $28 and reiterates a Buy rating on the shares following the company's Q3 results.

SPRO IS THE GUMMY OF THE DAY!

(LAZR IS UP TOO MUCH 10%)
 
Van lets take CHWY out of Grandma's Gummie Basket.... We did well!!!!! Enough is enough.

Floor & Decor is back I saw it up big the other day FND... might be a good swap.
 
AVNT- This stk keeps showing up on my screens I don't know why. It's doubled basically. I don't remember covering it but I must of typed it a few times in because it's on my watch lists.

STC- Yikes I blew another one. I'm sorry. I sold too soon. +$3 yesterday! After I held it all that time in the IFN Portfolio. Like Trane... Ugh.

TER- While we are on the topic of bad sells this one we are not so far behind but it was very very dead and now has woken up. The type of stock you buy and it goes down because of sector. Should of just held- we had a purchase price under $100. Now $120.

ALLY-Theme here we can buy back some of our ideas that worked but are still working (unfortunately)

MVIS- My old projector from a pen stk why was that up the other day? We'll look into that later.
 
Piper says NGM Biopharmaceuticals R&D day highlights 'undervaluation' of shares NGM, MRK Piper Sandler analyst Yasmeen Rahimi said NGM Biopharmaceuticals' (NGM) "well-executed Virtual R&D day" yesterday highlighted what she expects to be a "catalyst-rich 2021" as well as stressing the current undervaluation of the shares. Following the event, she is "convinced more than ever" that NGM will continue to bring multiple assets into clinical development and that Merck (MRK) is "fully committed" to its partnership with the company to expand the pipeline. Rahimi has an Overweight rating and $30 price target on NGM shares.

Just a thought MRK is tied in pretty tight here to NGM would they maybe buy them? The M&A seems strong now....
 
You must log in or register to reply here.
Back
Top